Investment Rating - The report maintains a "Recommendation" rating for the consumer discretionary sector [5] Core Insights - The beauty and personal care segment shows strong growth, with companies like Proya achieving over 10 billion RMB in revenue for the first time, and significant increases in net profit [3][26] - The retail sector is expanding, with ALDI opening new stores and achieving record sales, while companies like Yonghui Supermarket are recovering from previous losses [25][34] - The travel and leisure industry is also seeing growth, with increased flight operations and significant revenue increases for companies like Xiangyuan Culture [21][34] Summary by Sections Market Performance - For the week of April 21-25, 2025, the Shenyin Wanguo indices for retail, social services, and beauty care sectors showed mixed performance, with beauty care up by 3.80% [10][12] - The beauty care sub-sector outperformed others, with individual products and cosmetics increasing by 7.11% and 4.89% respectively [11] Key Industry Data and News - Proya's revenue for 2024 reached 10.778 billion RMB, marking a 21% increase, while its net profit rose by 30% [3][26] - Other companies like Marubi and Betaini also reported significant revenue growth, with Marubi's revenue increasing by 33.4% in 2024 [3][29] - The travel sector saw a rise in flight operations, with nearly 106,000 flights executed in the week of April 14-20, 2025, reflecting an 8.7% increase year-on-year [21][23] Key Company Announcements - Proya's Q1 2025 revenue was 2.359 billion RMB, a year-on-year increase of 8.13% [26] - Marubi reported a Q1 2025 revenue of 847 million RMB, up 28.01% from the previous year [29] - Bubble Mart's Q1 2025 revenue surged by 165%-170%, with overseas revenue increasing by over 475% [33]

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][19] Core Views - The company achieved a revenue of 10.778 billion with a year-on-year growth of 21.04% and a net profit of 1.552 billion, reflecting a year-on-year increase of 30% in 2024. The profit growth is attributed to cost reduction and efficiency improvements, solidifying its position as a leading domestic beauty brand [1][7][4] - The company is leveraging its main brand's single product strategy and the rapid rise of emerging brands to build a strong brand matrix, gradually advancing towards becoming a beauty group [4][19] - The company is expected to increase its marketing investments due to the intensified product launches in the second quarter of this year and the continuous incubation of new brands [4][19] Revenue and Profitability - In 2024, the main brand Proya generated revenue of 8.581 billion, growing by 19.55% year-on-year, while the online channel revenue reached 10.234 billion, with a year-on-year increase of 23.68% [2][9] - The gross profit margin for 2024 was 71.39%, an increase of 1.46 percentage points year-on-year, driven by product structure optimization and reduced costs [12][3] - The company plans to distribute a cash dividend of 11.90 per 10 shares, which accounts for 40.07% of the net profit [7][1] Financial Forecasts - The company forecasts revenues of 12.428 billion, 13.993 billion, and 15.449 billion for 2025, 2026, and 2027 respectively, with corresponding net profits of 1.869 billion, 2.144 billion, and 2.388 billion [5][21] - The projected PE ratios for 2025, 2026, and 2027 are 18, 16, and 14 respectively [4][21] Brand and Channel Performance - The emerging brands OR and Original Color Pot achieved revenue growth rates of 71.14% and 138.36% respectively, enhancing the overall brand matrix competitiveness [2][8] - The online direct sales and distribution channels saw revenue increases of 20.35% and 38.40% respectively, while offline channel revenue decreased by 13.63% [9][2]

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][18] Core Views - The company's performance is under pressure due to multiple factors, including disappointing sales during major promotional events and high marketing costs on platforms like Douyin. The net profit for 2024 is expected to decline by 33.53% year-on-year, while revenue is projected to grow by 3.87% [1][7] - The main brand, Winona, continues to have strong consumer recognition in the sensitive skin care sector, despite short-term performance challenges. The company is actively expanding into the medical beauty and health sectors, which may drive long-term growth [4][18] - The company is currently in a brand matrix development and channel strategy transformation phase, with high expense ratios impacting profitability during this transition [4][18] Financial Performance Summary - For 2024, the company is expected to achieve revenue of 57.36 billion, a year-on-year increase of 3.87%, and a net profit of 5.03 billion, a year-on-year decrease of 33.53% [1][7] - The first quarter of 2025 shows a revenue of 9.49 billion, down 13.51% year-on-year, and a net profit of 0.28 billion, down 83.97% year-on-year [8] - The gross margin for 2024 is projected at 73.74%, a slight decrease of 0.16 percentage points year-on-year, while the first quarter of 2025 shows an improvement in gross margin to 77.47% [12][3] Brand and Channel Performance - In 2024, the main brand Winona generated revenue of 49.1 billion, a decrease of 2.8% year-on-year, while the sub-brand Winona Baby saw a revenue increase of 34.03% to 2 billion [2][8] - Online sales channels achieved revenue of 39.12 billion in 2024, a year-on-year increase of 10.13%, with significant growth on platforms like Douyin and JD [9][2] - The offline channel revenue decreased by 10.72% year-on-year to 12.74 billion, indicating a shift in consumer purchasing behavior towards online platforms [9][2] Expense and Profitability Metrics - The sales expense ratio for 2024 is projected to increase by 2.71 percentage points year-on-year to 49.97%, reflecting higher marketing investments [12][3] - The company plans to distribute a cash dividend of 6 yuan per 10 shares for 2024, representing a payout ratio of 50% of net profit [1][7] - The net profit forecast for 2025-2026 has been revised down to 6.87 billion and 8.22 billion, respectively, due to prolonged new product development cycles and high expense ratios during the transformation period [4][18]

Core Viewpoint - The launch of the innovative transdermal collagen technology by Furuida Biotech's brand KeyC marks a significant advancement in the field of recombinant collagen protein, enhancing skin penetration rates by 27.5 times compared to traditional methods, indicating a disruptive innovation in the industry [1][4]. Group 1: Technology and Innovation - The newly developed transdermal collagen technology allows for significantly improved skin penetration, overcoming the traditional barrier that large molecular collagen could not penetrate the stratum corneum [3][4]. - The research team utilized cell-penetrating peptides to link with recombinant type III collagen, effectively delivering collagen to deeper skin layers, akin to a vehicle transporting goods [3][4]. - Experimental data shows that the transdermal collagen significantly enhances the expression of key structural proteins in the skin, promoting repair and regeneration, thus providing a comprehensive anti-aging effect [4]. Group 2: Product Launch and Efficacy - Furuida Biotech has launched a series of products featuring the new transdermal collagen, including a collagen essence and a collagen mask, which have shown promising results in reducing fine lines and improving skin texture [5]. - Third-party SGS certification indicates that after 10 minutes of application, fine lines between the eyebrows were reduced by 13.15%, and after 28 days, the reduction reached 23.24% [5]. Group 3: Market Position and Strategy - Furuida Biotech aims to leverage its research capabilities and industry leadership to establish recombinant collagen as a significant growth segment, following the success of hyaluronic acid [7]. - The company plans to enhance its investment in the medical beauty brand KeyC and strengthen collaborations with research institutions and hospitals to capitalize on the emerging opportunities in the recombinant collagen market [7].

Core Insights - The Chinese beauty brand Proya has achieved its first 10 billion yuan revenue milestone, with total revenue reaching 10.778 billion yuan in 2024, marking a year-on-year growth of approximately 21% [1][3] - Proya's net profit attributable to shareholders for 2024 was 1.552 billion yuan, reflecting a year-on-year increase of 30% [1] - The brand's online sales channel remains dominant, contributing 95% to total revenue, although high marketing expenses associated with this channel are putting pressure on profit margins [1][7] Revenue and Profit Growth - Proya's total revenue for 2024 was 10.778 billion yuan, a 21.04% increase compared to the previous year, but this growth rate has significantly declined from 39.45% in 2023 [3] - The core brand Proya generated 8.581 billion yuan in revenue, up 19.55%, which is a notable decrease from the previous years' growth rates of around 36% [3] Brand Strategy and Product Development - Proya is intentionally reducing the core brand's contribution to overall revenue, with its share decreasing from 82.74% in 2022 to 79.69% in 2024 [5] - The company is focusing on the sunscreen category, launching new products and appointing Liu Yifei as the global spokesperson for its sunscreen line [5] - The color cosmetics brand Caitang has become the second-largest revenue source, generating 1.191 billion yuan, but its growth has sharply declined from previous years [6] Online Sales Performance - Proya's online sales reached 10.234 billion yuan in 2024, a year-on-year increase of 23.68%, with online sales accounting for an increasing proportion of total revenue [7] - The brand's flagship store on Tmall achieved the highest sales in the beauty category, indicating strong online performance [7] Marketing and Expenses - Proya's sales expenses for 2024 were 5.161 billion yuan, representing 47.88% of total revenue, an increase from 44.61% the previous year [8] - Marketing expenses rose significantly, with promotional costs increasing by 30.22% year-on-year [8] - Despite revenue growth, Proya's sales net profit margin was 14.71%, only slightly up from the previous year, indicating challenges in profitability [8]

Market Performance - The recombinant protein sector declined by 1.56%, ranking among the top losers in concept sectors as of April 25 [1][2] - Notable stocks within the sector that hit the daily limit down include Jiangsu Wuzhong and Weiming Pharmaceutical, while stocks like HJ Bio, Wanfang Development, and Aladdin saw significant declines [1] Top Gainers and Losers - Among the top gainers in the recombinant protein sector, Borui Pharmaceutical, BeiDa Pharmaceutical, and Tonghua Dongbao increased by 4.39%, 2.42%, and 2.31% respectively [1] - The sector experienced a net outflow of 158 million yuan, with 22 stocks seeing net outflows, and five stocks exceeding 10 million yuan in outflows [2] Capital Flow Analysis - The stock with the highest net outflow was Xilong Science, with a net outflow of 190 million yuan, followed by Furida and Dezhan Health with outflows of 19.41 million yuan and 19.18 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Zhongyuan Qihua, Zhifei Biological, and Chengdu Xian Dao, with inflows of 26.63 million yuan, 25.06 million yuan, and 17.51 million yuan respectively [2][3]

证券代码：600223 证券简称：福瑞达 编号：临 2025-013 鲁商福瑞达医药股份有限公司 关于 2025 年第一季度主要经营数据的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号行业信 息披露：第十三号——化工》的要求，现将鲁商福瑞达医药股份有限公司（以下 简称"公司"）2025 年第一季度主要经营数据披露如下： 一、2025 年第一季度公司主要产品的产量、销量及收入实现情况 | 主要产品 | 产量（件） | 销量（件） | 营业收入（元） | | --- | --- | --- | --- | | 护肤类 | 25,224,291.90 | 26,608,754.90 | 526,345,075.93 | 二、2025 年第一季度公司主要产品和原材料的价格变动情况 护肤类产品 2025 年第一季度平均售价同比下降 0.75%。 （二）主要原材料价格波动情况 公司主要原材料有包装物、保湿剂、活性物、乳化剂、油脂等。 1、包装物 2025 年第一季 ...

证券代码：600223 证券简称：福瑞达 编号：临 2025-014 鲁商福瑞达医药股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 问题征集方式：投资者可于 2025 年 4 月 28 日（星期一）至 5 月 7 日 （星期三）16:00 前将需要了解的情况和相关问题通过电子邮件的形式发送至公 司投资者关系邮箱：lsfrd600223@163.com。公司将在业绩说明会上对投资者普 遍关注的问题进行回答。 鲁商福瑞达医药股份有限公司（以下简称"公司"）于 2025 年 4 月 25 日披露 公司 2025 年第一季度报告，为了便于广大投资者更全面深入地了解公司 2025 年第一季度业绩和经营情况，公司拟于 2025 年 5 月 8 日（星期四）15:00-16:00 举行 2025 年第一季度业绩说明会，就投资者普遍关心的问题进行交流。 一、业绩说明会类型 本次投资者说明会以网络文字互动的形式召开，公司将针对 2025 年第一季 度业绩和经营情况 ...

Group 1: Financial Performance - In Q1 2025, the company achieved operating revenue of 876 million yuan and a net profit attributable to the parent company of 51 million yuan [1] - As of March 31, 2025, total assets amounted to 6.044 billion yuan, with net assets attributable to the parent company at 4.156 billion yuan [1] Group 2: Cosmetics Business - The cosmetics segment generated operating revenue of 526 million yuan in Q1, with a gross margin of 61.06% [1] - The Yilian brand experienced significant growth, with Q1 revenue of 250 million yuan, representing a 25% year-on-year increase [1] - The Yilian spray product line announced a new spokesperson, Zhang Linghe, leading to a 69% increase in sales [1] - The focus on the "Pongrun" cream as a core product resulted in a 65% year-on-year increase in sales for the Pongrun water and milk products [1] - The Aier Doctor brand accelerated its brand adjustment, achieving Q1 revenue of 236 million yuan [1] - The Aier Doctor brand launched new products, including a "probiotic special gift box" and a new cleansing product [1] - The Kemi brand focused on "collagen anti-aging" and implemented a strategy centered on collagen products, ranking first in popularity on Douyin for collagen essence [1] Group 3: Pharmaceutical Business - The pharmaceutical segment maintained stable performance with operating revenue of 108 million yuan and a gross margin of 54.80% [2] - The company continued to advance drug research and development, launching two functional beverages during the reporting period [2] - Organizational changes were made to adapt to market policy changes, including the establishment of a KA sales department and a digital marketing department [2] - The company developed 200 new clients in hospital and OTC channels [2] Group 4: Raw Materials and Additives - The raw materials and additives segment achieved operating revenue of 86 million yuan with a gross margin of 39.54% [2] - The raw materials segment focused on technological innovation, obtaining two new authorized invention patents [2] - The company established a national-level postdoctoral research workstation and progressed with domestic and international pharmaceutical-grade project applications [2] - The sales of hyaluronic acid raw materials increased by 32% year-on-year, with an 11 percentage point increase in gross margin [2]

| 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.0500 | 0.0600 | -16.67 | 0.1300 | | 每股净资产（元） | 4.09 | 4.01 | 2 | 3.78 | | 每股公积金(元) | 0.6 | 0.6 | 0 | 0.61 | | 每股未分配利润(元) | 2.22 | 2.16 | 2.78 | 1.99 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 8.76 | 8.91 | -1.68 | 12.72 | | 净利润(亿元) | 0.51 | 0.59 | -13.56 | 1.29 | | 净资产收益率(%) | 1.23 | 1.46 | -15.75 | 3.42 | 数据四舍五入，查看更多财务数据>> 一、主要会计数据和财务指标 二、前10名无限售条件股东持股情况 三、分红送配方案情况 本次公司不分配不转赠。 前十大流通股东累计持有： 59963.59万股， ...